India, Aug. 31 -- BioVie Inc. (BIVI), a clinical-stage biopharmaceutical company, on Monday reported dosing the last patient in the Phase 2 ADDRESS-LC trial for Bezisterim in treating neurological symptoms of Long COVID.
Long COVID has affected around 17 million to 20 million people in the U.S. alone in the aftermath of the COVID-19 pandemic, and may manifest with neurological symptoms like fatigue, cognitive dysfunction, post-exertion malaise, and sleep disturbances. About 50% of Long COVID patients develop these persistent or intermittent symptoms alongside chronic inflammation and immune system dysregulation. There are currently no FDA-approved medications for the treatment of this disease.
Bezisterim (NE3107) is an investigational ora...